Literature DB >> 17005763

Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.

Mar Guilarte1, Javier Santos, Inés de Torres, Carmen Alonso, María Vicario, Laura Ramos, Cristina Martínez, Francesc Casellas, Esteban Saperas, Juan Ramón Malagelada.   

Abstract

BACKGROUND: Increased numbers of mast cells and mast cell activation in distal gut segments are associated with symptom onset and severity in irritable bowel syndrome (IBS). Although upper gut symptoms are common, mast cells have not been thoroughly evaluated in proximal gut in IBS patients.
METHODS: Jejunal biopsies obtained by Watson's capsule, aspiration of intestinal fluid and one blood sample were obtained in 20 diarrhoea-predominant patients with IBS (D-IBS) and 14 healthy volunteers (H). Psychological stress (Holmes-Rahe Scale) and depression (Beck's Depression Inventory) were evaluated at baseline and food and respiratory allergy excluded. Biopsies were processed for H&E staining and microscopic inflammation assessed by counting intraepithelial lymphocytes. Mast cells in lamina propria were counted by immunohistochemistry with CD117 (c-kit). Tryptase concentration was measured in intestinal fluid and serum.
RESULTS: D-IBS patients showed higher psychological stress than healthy volunteers (D-IBS: 203 (SD 114) v H: 112 (SD 99); p = 0.019). Immunohistochemical staining of jejunal mucosa revealed mild increase in intraepithelial CD3+ cells in D-IBS patients (D-IBS: 15.3 (SD 5.5; 95% CI 12.7 to 17.9) v H: 10.3 (SD 3.9; 95% CI 8.0 to 12.5); p = 0.006). Moreover, D-IBS patients showed marked increase in mast cells numbers (D-IBS: 34 (SD 9.3); H: 15.3 (SD 4.4) mast cells/hpf; p<0.001) and higher tryptase concentration in jejunal fluid (D-IBS: 0.45 (SD 0.38); H: 0.09 (SD 0.10) microg/l; p = 0.005). Upper gut symptoms were not associated with gender, mast cell counts, jejunal tryptase or basal stress.
CONCLUSION: This jejunal mucosal inflammatory profile may help identify diarrhoea-predominant IBS, a stress-related disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005763      PMCID: PMC1856785          DOI: 10.1136/gut.2006.100594

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  52 in total

1.  Activation of the mucosal immune system in irritable bowel syndrome.

Authors:  Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

Review 2.  Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function.

Authors:  Y Taché; M H Perdue
Journal:  Neurogastroenterol Motil       Date:  2004-04       Impact factor: 3.598

3.  The Social Readjustment Rating Scale.

Authors:  T H Holmes; R H Rahe
Journal:  J Psychosom Res       Date:  1967-08       Impact factor: 3.006

4.  Granule changes of human and murine endocrine cells in the gastrointestinal epithelia are characteristic of piecemeal degranulation.

Authors:  Enrico Crivellato; Domenico Ribatti; Franco Mallardi; Carlo Alberto Beltrami
Journal:  Anat Rec       Date:  2002-12-01

5.  Are gastrointestinal mucosal mast cells increased in patients with systemic mastocytosis?

Authors:  Sabine I Siegert; Joachim Diebold; Dagmar Ludolph-Hauser; Udo Löhrs
Journal:  Am J Clin Pathol       Date:  2004-10       Impact factor: 2.493

6.  Human intestinal mucosal mast cells: expanded population in untreated coeliac disease.

Authors:  S Strobel; A Busuttil; A Ferguson
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

7.  Age-related decline in rectal mucosal lymphocytes and mast cells.

Authors:  Simon P Dunlop; David Jenkins; Robin C Spiller
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-10       Impact factor: 2.566

Review 8.  Postinfectious irritable bowel syndrome.

Authors:  Robin C Spiller
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

9.  Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis.

Authors:  L B Schwartz; D D Metcalfe; J S Miller; H Earl; T Sullivan
Journal:  N Engl J Med       Date:  1987-06-25       Impact factor: 91.245

10.  Gastrointestinal dysfunction in systemic mastocytosis. A prospective study.

Authors:  J A Cherner; R T Jensen; A Dubois; T M O'Dorisio; J D Gardner; D D Metcalfe
Journal:  Gastroenterology       Date:  1988-09       Impact factor: 22.682

View more
  115 in total

Review 1.  Mechanisms of diarrhea.

Authors:  Christina M Surawicz
Journal:  Curr Gastroenterol Rep       Date:  2010-08

Review 2.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome.

Authors:  Bin Feng; Jun Ho La; Erica S Schwartz; G F Gebhart
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

3.  Mast cells and intestinal motility disorders (mastocytic enteritis/colitis).

Authors:  David F Schaeffer; Richard Kirsch; Robert H Riddell
Journal:  Dig Dis Sci       Date:  2012-05       Impact factor: 3.199

Review 4.  Chymase inhibition as a pharmacological target: a role in inflammatory and functional gastrointestinal disorders?

Authors:  S Heuston; N P Hyland
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

5.  Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

6.  Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.

Authors:  Olga Bednarska; Susanna A Walter; Maite Casado-Bedmar; Magnus Ström; Eloísa Salvo-Romero; Maria Vicario; Emeran A Mayer; Åsa V Keita
Journal:  Gastroenterology       Date:  2017-07-13       Impact factor: 22.682

Review 7.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.

Authors:  Lena Ohman; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01-26       Impact factor: 46.802

Review 8.  Inflammation in irritable bowel syndrome: Myth or new treatment target?

Authors:  Emanuele Sinagra; Giancarlo Pompei; Giovanni Tomasello; Francesco Cappello; Gaetano Cristian Morreale; Georgios Amvrosiadis; Francesca Rossi; Attilio Ignazio Lo Monte; Aroldo Gabriele Rizzo; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 9.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

10.  Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia.

Authors:  M M Walker; N J Talley; M Prabhakar; C J Pennaneac'h; P Aro; J Ronkainen; T Storskrubb; W S Harmsen; A R Zinsmeister; L Agreus
Journal:  Aliment Pharmacol Ther       Date:  2009-01-17       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.